MAURITS W. GEERLINGS, M.D., M.B.A.
Dr. Geerlings co-founded Formula Pharmaceuticals in 2009 and has more than 18 years of biopharmaceutical experience including general management, business development, international operations, biotech start-up, financing, government affairs, academic research, and strategic planning. Previously, Dr. Geerlings was a co-founder and former Director and Chief Operating Officer of Actinium Pharmaceuticals, an oncology focused biotechnology company; lead business development at Infinity Pharmaceuticals, a publicly traded oncology focused company; and served as Vice President, Business Development at Prism Pharmaceuticals, a privately-held biopharmaceutical company focusing on acute care medicines. Prior to joining Prism Pharma, Dr. Geerlings led business development activities in a variety of therapeutic areas with a predominant focus on oncology at Cephalon Inc., Alexion Pharmaceuticals and the Ludwig Institute for Cancer Research. Dr. Geerlings earned his M.D. from The University of Utrecht, Faculty of Medicine, Utrecht, The Netherlands, and his M.B.A. from The George Washington University in Washington, DC. He holds an M.S. from the University of Utrecht, The Netherlands.
STEVEN J. FEDER, ESQ.
Mr. Feder has 22 years of experience counseling entrepreneurs, executives, directors and corporate boards of directors for businesses at all stages of growth and in a variety of industries. He is a founding member of GenCounsel, LLC, an innovative business services company bringing experienced senior in-house lawyers together with businesses under a managed cost model. Previously, Mr. Feder was Senior Vice President and General Counsel of Safeguard Scientifics, Inc. and a partner at the law firm, Pepper Hamilton LLP. Earlier, Mr. Feder was also with the law firms, White and Williams LLP and Ballard Spahr, where he focused primarily on general corporate, M&A and securities matters for early stage, growth companies and mature businesses. He received his law degree from Temple University School of Law and his undergraduate degree in education from Temple University's College of Education.
VIDAL DE LA CRUZ, Ph.D
Over the past 2 decades, Dr. De la Cruz had leading roles in drug discovery and development, including in the area of immunology, oncology and biologics. From 2004-2011, Dr. de la Cruz led research and business development activities at Cytokine PharmaSciences (CPSI), in his latest capacity as Vice President. He joined CPSI in 2001 as Director, Preclinical Research. Upon the acquisition of CPSI by Ferring in 2011, Dr. De la Cruz founded Fomento Pharma, a drug development consultancy serving clients in the pharmaceutical and biotechnology arena. Prior to joining CPSI, Dr. de la Cruz co-founded Proxima Genetics, Inc. in 2000 and served as Executive Vice President and Scientific Director. From 1998 to 2000 he was Section Head, Department of Microbiology and Immunology at Roche. Previously, Dr. De la Cruz led research programs at Myriad Genetics, Inc., Cortech, Inc., and at MedImmune, Inc. in many areas of preclinical research that encompassed molecular biology and immunology, and in fields that included oncology, infectious diseases, inflammation and autoimmunity. His achievements include more than four dozen research publications, many in high profile scientific journals, several patents, and co-invention of peptide phage display. Dr. de la Cruz received his PhD in Cell & Molecular Biology from University of California, Los Angeles, and was a Postdoctoral Fellow at The National Institute of Allergy and Infectious Diseases, National Institutes of Health.
ROBERT (“BOB”) HRUBIEC, Ph.D, JD
Dr. Hrubiec is an intellectual property attorney with over 25 years of experience in all aspects of intellectual property specializing in pharmaceutical, biotechnology and medical device/diagnostic patent management, strategic IP evaluation, litigation support, business development, mergers/acquisitions, licensing, FDA regulations, trademarks and patent preparation and prosecution. Dr. Hrubiec is the founder and President of Innoventiv IP, an intellectual property management and consulting company. Prior to founding Innoventiv IP in 2012, Dr. Hrubiec was Vice President and Chief Intellectual Property Counsel at Cephalon, Inc., a mid-sized pharmaceutical company located in Frazer, Pennsylvania, where he was responsible for creating, developing and managing the company’s global IP department. He was also responsible for all IP aspects of business development. Prior to joining Cephalon in 1999, Dr. Hrubiec was an intellectual property attorney with GlaxoSmithKline and also directed a research laboratory at Cytogen Corporation focused on cytotoxic agents conjugated to monoclonal antibodies for use in treating cancer. Dr. Hrubiec received his Ph.D. in synthetic organic chemistry from the University of Connecticut followed by a postdoctoral fellowship in pharmacology/molecular biology at the Yale Medical School Comprehensive Cancer Center. He obtained his law degree from the North Carolina Central University School of Law and is licensed in North Carolina, Pennsylvania and the USPTO.
JEFFREY (“JEFF”) A. MATTIS, Ph.D
Dr. Mattis is a biopharmaceutical executive with more than 30 years of experience in the development of biopharmaceuticals. In 1979 Dr. Mattis joined Centocor where he served for 18 years, most recently as Vice President of Pharmaceutical Development. While at Centocor, he was instrumental in the technical development of several biopharmaceuticals approved for the U.S. and multinational markets. These include ReoPro®, an anti-platelet drug for use in coronary angioplasty and Remicade®, a drug for treatment of Crohn’s disease and rheumatoid arthritis. After a short period of consulting to emerging biotechnology companies and universities, Dr. Mattis joined Molecular Targeting Technologies, Inc. (MTTI) as Sr. Vice President of Scientific and Regulatory Affairs. MTTI is a privately held biotechnology company primarily focused on the development of small molecules for the molecular imaging of cardiovascular diseases and cancer. MTTI is also developing innovative Zn-DPA technology developed at the University of Notre Dame for the detection anionic cell membranes, a marker of apoptosis.
CHRISTOPHER B. HEGARTY, CPA
Mr. Hegarty is a Certified Public Accountant in Pennsylvania and has over 25 years of accounting experience. He specializes in providing accounting services to privately-owned, closely-held businesses and their owners. He is a Principal in the professional services firm of CliftonLarsonAllen (CLA) and leads their delivery of accounting outsourcing services in the Delaware Valley. Chris has served clients in the healthcare and life sciences industries as well as the manufacturing, retailing and industries. He has assisted emerging organizations in setting up accounting systems and control environments, as well as helped organizations transform their accounting and finance functions through periods of high growth and transition. Chris has expertise in traditional accounting and audit services, as well as a variety of operational and financial areas. Chris earned his Bachelor of Arts degree in Accounting from The Catholic University of America in Washington, D.C.
|Copyright 2015 Formula
Page Updated: 02/27/2017 09:35:16 AM